These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 18310292)

  • 1. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
    Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
    Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
    Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
    Vanderweele DJ; Rudin CM
    Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells.
    Cerovac V; Monteserin-Garcia J; Rubinfeld H; Buchfelder M; Losa M; Florio T; Paez-Pereda M; Stalla GK; Theodoropoulou M
    Cancer Res; 2010 Jan; 70(2):666-74. PubMed ID: 20068168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
    Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
    Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
    Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
    Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET; Cao C; Niermann K; Mu Y; Zeng F; Hallahan DE; Lu B
    Oncogene; 2005 Aug; 24(35):5414-22. PubMed ID: 15940265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells.
    Iwamaru A; Kondo Y; Iwado E; Aoki H; Fujiwara K; Yokoyama T; Mills GB; Kondo S
    Oncogene; 2007 Mar; 26(13):1840-51. PubMed ID: 17001313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
    Mondesire WH; Jian W; Zhang H; Ensor J; Hung MC; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2004 Oct; 10(20):7031-42. PubMed ID: 15501983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
    Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
    J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.
    Edinger AL; Linardic CM; Chiang GG; Thompson CB; Abraham RT
    Cancer Res; 2003 Dec; 63(23):8451-60. PubMed ID: 14679009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.